Peripheral photon and neutron doses from prostate cancer external beam irradiation

Calculation of Photoneutron Contamination of Varian Linac in ICRU Soft-Tissue Phantom Using MCNPX Code

Purpose

The aim of this research was to calculate the fluence, dose equivalent (DE), and kerma of thermal, epithermal and fast photoneutrons separately, within ICRU soft-tissue-equivalent phantom in the radiotherapy treatment room, using MCNPX Monte Carlo code.

Materials and Methods

For this purpose, 18 MV Varian Linac 2100 C/D machine was simulated and desired quantities were calculated on the central axis and transverse directions at different depths.

Results

Maximum fluence, DE and kerma of total photoneutrons on central axis of the phantom were 43.8 n.cm^-2.Gy^-1, 0.26, and 3.62 mGy.Gy^-1, at depths 2, 0.1, 0.1 cm, respectively. At any depth, average of fluence, DE and kerma in the outer area of the field were less than the inner area and in general were about 72%, 52%, and 45%, respectively.

Conclusion

According to this research, within the phantom; variation of fluence, DE and kerma in transverse direction were mild, and along the central axis at shallow area were sharp. DE of fast photoneutrons at shallow and deep areas were one order of magnitude greater than thermal photoneutrons.

NOVEL 'PHOTONEUTRON VOLUME DOSE EQUIVALENT' HYPOTHESIS AND METHODOLOGY FOR SECOND PRIMARY CANCER RISK ESTIMATION IN HIGH-ENERGY X-RAY MEDICAL ACCELERATORS

A novel 'photoneutron (PN) volume dose equivalent' methodology was hypothesized and applied for the first time for estimating PN second primary cancer (PN-SPC) risks in high-energy X-ray medical accelerators. Novel position-sensitive mega-size polycarbonate dosimeters with 10B converter (with or without cadmium covers) were applied for determining fast, epithermal and thermal PN dose equivalents at positions on phantom surface and depths. The methodology was applied to sites of tumors such as brain, stomach and prostate in 47 patients. The PN-SPC risks were estimated for specific organs/tissues using linear International Commission on Radiological Protection cancer risks and were compared with some available data. The corresponding PN-SPC risk estimates ranged from 1.450 × 10-3 to 1.901 cases per 10 000 persons per Gray. The method was applied to 47 patients for estimating PN-SPC risks in patients undergoing radiotherapy. The PN-SPC risk estimates well match those calculated by simulation but are comparatively different from those estimated by 'PN point dose equivalent' methods, as expected.

OUT-OF-FIELD DOSE MEASUREMENTS FOR 3D CONFORMAL AND INTENSITY MODULATED RADIOTHERAPY OF A PAEDIATRIC BRAIN TUMOUR

The purpose of this study was to measure out-of-field organ doses in clinical conditions in anthropomorphic paediatric phantoms which received a simulated treatment of a brain tumour with intensity modulated radiotherapy (IMRT) and 3D conformal radiotherapy (3D CRT). Organ doses measured with radiophotoluminescent and thermoluminescent dosemeters were on average 1.6 and 3.0 times higher for the 5 y-old than for the 10 y-old phantom for IMRT and 3D CRT, respectively. A larger 5-y to 10-y organ dose ratio for 3D CRT can be explained because the use of a mechanical wedge for the 5-y-old 3D CRT phantom treatment increased out-of-field doses. Due to different configurations of the radiation fields, for both phantoms, the IMRT technique resulted in a higher non-target brain dose and higher eye doses but lower thyroid doses compared to 3D CRT. For 3D CRT (which used a non-coplanar field configuration), eye doses were 3-6% and for IMRT (which used a coplanar field configuration) 27-30% of the treatment dose, respectively. For thyroid and more distant organs, doses were less than 1% of the treatment dose. Comparison of measured doses and doses calculated by the treatment planning system (TPS) showed that the TPS underestimated out-of-field doses both for IMRT and 3D CRT.